CYTT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYTT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Cyteir Therapeutics's Capital Expenditure for the three months ended in Sep. 2023 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was $0.00 Mil.
GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.
The historical data trend for Cyteir Therapeutics's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyteir Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Capex-to-Revenue | - | - | - | - |
Cyteir Therapeutics Quarterly Data | ||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Capex-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Cyteir Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's Capex-to-Revenue falls into.
Cyteir Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-0.312) | / | 0 | |
= | N/A |
Cyteir Therapeutics's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (0) | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyteir Therapeutics (OTCPK:CYTT) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Thank you for viewing the detailed overview of Cyteir Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Joseph S Zakrzewski | director | 509 WATERVIEW PLACE, NEW HOPE PA 18938 |
John F Thero | director | C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921 |
Adam M Veness | officer: General Counsel | C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
Stephen H. Sands | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Jeffrey Humphrey | director | C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
Droia Invest Ii Scsp | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Janwillem Naesens | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Sa Ihl | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Karen Hong | director | 69 PARKSIDE DRIVE, PRINCETON NJ 08540 |
Bv Wepaven | 10 percent owner | BRUSSELSESTEENWEG 11, MEISE C9 1860 |
Luc Verelst | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Df Ii Gp Sarl | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Timothy Romberger | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Racquel Bracken | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
From GuruFocus
By Business Wire Business Wire • 11-12-2021
By Business Wire Business Wire • 09-20-2021
By Business Wire Business Wire • 09-01-2021
By Business Wire Business Wire • 08-31-2022
By Business Wire Business Wire • 03-23-2023
By Business Wire Business Wire • 12-16-2021
By Business Wire Business Wire • 08-01-2022
By Business Wire Business Wire • 01-03-2022
By Business Wire Business Wire • 04-25-2022
By Business Wire Business Wire • 05-31-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.